RxDoctor Payments Data

Alan Kirollos, MD

Cardiovascular Disease · Kinston, NCNPI 1881615706

Payments from drug & device makers

$4,073in general payments, 2019–2025

Across 59 payments — averaging $69.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biotronik Inc.$1K
  • Johnson & Johnson$164
  • Edwards Lifesciences$135
  • E.r. Squibb & Sons, L.L.C.$69
  • Boehringer Ingelheim$16
  • plus $66 from 5 others

What the payments were for

  • Travel & lodging$2,70566%
  • Food & beverage$1,27831%
  • Education$902%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,073 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$345,874
Medicare patients
774
Services billed
5,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban641$482,991
EntrestoSacubitril/Valsartan142$130,481
XareltoRivaroxaban104$80,892
Repatha SureclickEvolocumab78$57,767
JardianceEmpagliflozin42$36,362
MultaqDronedarone Hcl11$12,928
Ranolazine ErRanolazine143$7,505
Metoprolol Succinate803$7,295
BrilintaTicagrelor11$7,036
Isosorbide Mononitrate ErIsosorbide Mononitrate581$5,546
Atorvastatin Calcium710$4,874
Acebutolol Hcl87$4,632
Flecainide Acetate175$4,355
Spironolactone-HctzSpironolact/Hydrochlorothiazid114$4,347
Hydralazine Hcl422$4,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$130,481142 claims
Johnson & JohnsonXarelto$164$80,892104 claims
Boehringer IngelheimJardiance$16$36,36242 claims
Sanofi-aventis U.S. LLCMultaq$14$12,92811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Kinston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →